| Remozen (remogliflozin etabonate) / Islet Sci |
NCT00376038: Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes |
|
|
| Completed | 1 | 13 | RoW | GSK189075 oral tablets, metformin tablets | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | 10/06 | 10/06 | | |
NCT00504816: A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers |
|
|
| Completed | 1 | 22 | US | GSK189075, Brevicon | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | 01/08 | 04/08 | | |
NCT00532610: A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults |
|
|
| Completed | 1 | 78 | US | GSK189075 | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | 02/08 | 02/08 | | |
NCT00501462: A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function |
|
|
| Completed | 1 | 29 | US | GSK189075 | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency | 03/08 | 03/08 | | |
NCT00519480: A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin |
|
|
| Completed | 1 | 50 | US, Europe, RoW | GSK189075, Metformin, Placebo | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 04/08 | 04/08 | | |
NCT00625859: A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects |
|
|
| Completed | 1 | 27 | US | GSK189075, Bupropion, Placebo | GlaxoSmithKline | Diabetes Mellitus, Type 2 | 04/08 | 04/08 | | |
NCT00671424: A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide |
|
|
| Completed | 1 | 48 | US | Hydrochlorothiazide (HCTZ), Remogliflozin etabonate (GSK189075), Furosemide | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | 05/08 | 05/08 | | |
NCT00501683: A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers |
|
|
| Completed | 1 | 8 | US | Radiolabelled GSK189075 | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | | | | |
NCT00501397: A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers |
|
|
| Completed | 1 | 22 | US | ketoconazole, GSK189075 | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | | | | |
NCT00501930: A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers |
|
|
| Completed | 1 | 12 | US | GSK189075 | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | | | | |
NCT00559884: A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects |
|
|
| Completed | 1 | 36 | US | GSK189075 (Modified and immediate release formulations) | GlaxoSmithKline | Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2 | | | | |
